{'fraction_non_alphanumeric': 0.019756838905775075, 'fraction_numerical': 0.001519756838905775, 'mean_word_length': 5.864583333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes

Tuberculosis (TB) risk might be increased in patients with diabetes by factors other than hyperglycaemia, such as dyslipidaemia. Host lipids are essential energy sources used by mycobacteria to persist in a latent TB state. A potential therapy targeting cholesterol catabolism of mycobacteria has been proposed, but the potential of cholesterol‐lowering drugs as anti‐TB therapy is unclear. The purpose of this study was to determine the effects of ezetimibe, a 2‐azetidinone cholesterol absorption inhibitor, on intracellular mycobacteria survival and dormancy.